FDA's 503B GLP-1 Compounding Ban Reaches Its Final Hour — What Happens After the Comment Window Closes

Today, June 29, 2026, the public comment period closes on one of the most consequential proposed FDA rules in the compounding pharmacy space in years. The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List — a move that would shut the door on large-scale compounded GLP-1 production even if drug shortages return. With the comment window now closed, the regulatory machinery moves forward.

The Proposal: What the FDA Is Actually Doing

On April 30, 2026, the FDA proposed a rule that would formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. 503B outsourcing facilities — the larger, FDA-regulated compounding operations serving hospitals, clinics, and healthcare systems — would lose the legal authority to produce these GLP-1 compounds in bulk.

The FDA's rationale centers on a statutory requirement: 503B compounders can only use bulk APIs when there is a clinical need that cannot be met by FDA-approved alternatives. The FDA concluded that since Ozempic, Wegovy, Mounjaro, and Zepbound are commercially available, no such clinical need exists.

This is a structural change — not just a response to current market conditions. The shortage designation was the legal scaffolding that allowed widespread compounding of these drugs over the past three years.

The Shortage Status Question

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, triggering an immediate enforcement crackdown. Tirzepatide returned to the shortage list in 2025 and remained there as of April 2026 — keeping a temporary 503A window open. But the proposed 503B exclusion is designed to prevent this kind of back-and-forth: a future shortage designation would not re-open 503B bulk compounding even if finalized.

The 503A Pathway Remains — For Now

503A compounding — individual prescriptions prepared at state-licensed sterile pharmacies for specific patients — is not directly targeted by this rule. Under 503A, a pharmacy can still prepare semaglutide or tirzepatide for an individual patient with a valid prescription and FDA-registered API with a Certificate of Analysis. This pathway is narrower, more expensive, and does not allow mass manufacturing or pre-compounding.

503A is under pressure from a separate direction: more than 40 state attorneys general have launched investigations into telehealth platforms using 503A compounders as a de facto commercial channel, arguing the volume undermines the individualized patient standard.

The Warning Letter Wave

During the week of June 15, 2026, the FDA issued 25 warning letters to telehealth companies for misleading promotional claims about compounded GLP-1 products — bringing the total to over 80 in the trailing 12 months. The enforcement theory is consistent: FDA evaluates whether marketing, taken as a whole, gives consumers the impression that a compounded product is FDA-approved or equivalent to an approved drug.

What Comes Next

With comments now closed, FDA reviews submissions and issues a final rule — expected within six to twelve months given the agency's current posture. If finalized, 503B outsourcing facilities will be barred from compounding these three compounds.

The more immediate calendar: July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee meets to vote on whether BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, and DSIP should be added to the 503A Bulk Drug Substances List. This is a separate proceeding — but it shows the FDA is simultaneously tightening its grip on GLP-1 compounding while potentially opening a formal legal pathway for certain research peptides.

What This Means for the Research Community

The GLP-1 compounding landscape as it existed from 2022 to 2025 is not coming back. Enforcement infrastructure is now fully in place: warning letters, pharmacy license revocations, civil lawsuits from Eli Lilly and Novo Nordisk, criminal referrals, and state AG investigations. Peptide Sciences (990,000 monthly visits) shut down March 6, 2026 with no warning — one of at least 8 major vendor closures since mid-2025. The crackdown that began targeting GLP-1 compounders swept the broader research peptide grey market along with it.

The July PCAC hearing represents a constructive counterpoint. A positive committee recommendation for BPC-157, TB-500, and the other five compounds would begin formal rulemaking toward a legal 503A compounding pathway — the first formal legal status these compounds would have in U.S. compounding law.